Ayazi et al. Level: III-3 44 subjects Bravo pH Clinical 100% 95% - - - - 98 (2009) (2) monitoring diagnosis Quality: [85–100] [76–100] [88–100] Patient selection: ? Time under pH Diagnostic Index test: ? 4 >4.2% case-control Reference study standard: Flow and timing: ? CX P3 Ayazi et al. Level: III-3 38 subjects Bravo pH Clinical Abnormal Abnormal Abnormal Abnormal - - Abnormal (2009) (3) (28 patients monitoring diagnosis combined combined combined combined combined Quality: and 10 Time (minimal clinical 48 hours: 48 hours: 48 hours: 48 hours: 48 hours: Patient selection: under pH 4 evidence of controls) 82% 100% 100% 67% 87% Diagnostic Index test: ? >4.2% GORD in case-control Abnormal Abnormal Abnormal Abnormal Abnormal Reference control study first or first or first or first or first or standard: population) second second second second second Flow and timing: 24 hours: 24 hours: 24 hours: 24 hours: 24 hours: CX 93% 100% 67% 83% 95% P3 Pandolfino Level: III-3 37 subjects Bravo pH Clinical 24-h: 67.5% 24-h: 89.7% 24-h: 86.2% 24-h: 74.5% 24-h: 6.55 24-h: 0.36 - et al. (2003) monitoring diagnosis Quality: 48-h: 64.9% 48-h: 94.8% 48-h: 92.3% 48-h: 74.0% 48-h: 12.48 48-h: 0.37 day 1 Patient selection: W: 83.8% W: 84.5% W: 83.3% W: 84.6% W: 5.4 W: 0.19 worst day Diagnostic Index test: ? (W)) case-control Reference Time under pH study standard: ? 4 >5.3% Flow and timing: CX P3 ? = unable to determine / unclear risk; = low risk; = high risk
Ayazi et al. (2009) (2) Diagnostic case-control study Level: III-3 Quality: Patient selection: ? Index test: ? Reference standard: Flow and timing: ? CX P3 44 subjects Bravo pH monitoring Time under pH 4 >4.2% Clinical diagnosis 100% [85–100] 95% [76–100] - - - - 98 [88–100] Ayazi et al. (2009) (3) Diagnostic case-control study Level: III-3 Quality: Patient selection: Index test: ? Reference standard: Flow and timing: CX P3 38 subjects (28 patients and 10 controls) Bravo pH monitoring Time under pH 4 >4.2% Clinical diagnosis (minimal clinical evidence of GORD in control population) Abnormal combined 48 hours: 82% Abnormal first or second 24 hours: 93% Abnormal combined 48 hours: 100% Abnormal first or second 24 hours: 100% Abnormal combined 48 hours: 100% Abnormal first or second 24 hours: 67% Abnormal combined 48 hours: 67% Abnormal first or second 24 hours: 83% - - Abnormal combined 48 hours: 87% Abnormal first or second 24 hours: 95% Pandolfino et al. (2003) Diagnostic case-control study Level: III-3 Quality: Patient selection: Index test: ? Reference standard: ? Flow and timing: CX P3 37 subjects Bravo pH monitoring day 1 worst day (W)) Time under pH 4 >5.3% Clinical diagnosis 24-h: 67.5% 48-h: 64.9% W: 83.8% 24-h: 89.7% 48-h: 94.8% W: 84.5% 24-h: 86.2% 48-h: 92.3% W: 83.3% 24-h: 74.5% 48-h: 74.0% W: 84.6% 24-h: 6.55 48-h: 12.48 W: 5.4 24-h: 0.36 48-h: 0.37 W: 0.19 - ? = unable to determine / unclear risk; = low risk; = high risk